Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Destiny Pharma Holdings plc (DEST) Ord GBP0.01

Sell:40.00p Buy:43.00p 0 Change: No change
Market closed Prices as at close on 6 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:40.00p
Buy:43.00p
Change: No change
Market closed Prices as at close on 6 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:40.00p
Buy:43.00p
Change: No change
Market closed Prices as at close on 6 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Destiny Pharma PLC is a United Kingdom-based clinical stage biotechnology company. The Company is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. The exeporfinium chloride (XF) Drug series is the Company’s anti-microbial drug platform and comprises the related XF and drugs described by Destiny Pharma (DPD) drug candidate. Its pipeline for the XF Drug products includes XF-73 Nasal, XF-73 Throat, XF-70 Dermal and XF-70 Lung. XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 is in the clinical development stage for the prevention of post-surgical staphylococcal infections. XF-73 has completed four Phase I /II A studies in Europe.

Contact details

Address:
Sussex Innovation Centre
Science Park Square, Falmer
BRIGHTON
BN1 9SB
United Kingdom
Telephone:
+44 (01273) 704440
Website:
https://www.destinypharma.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 23 September 2019 23/09/19
AGM 04 June 2019 04/06/19
Annual report 29 April 2019 29/04/19
Final results 09 April 2019 09/04/19

General stock information

EPIC:
DEST
ISIN:
GB00BDHSP575
Market cap:
£18.20 million
Shares in issue:
43.87 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Neil Clark
    Chief Executive Officer, Executive Director
  • William Love
    Founder, Chief Scientific Officer, Executive Director
  • Shaun Claydon
    Chief Financial Officer, Company Secretary
  • Jesus Gonzalez Moreno
    Chief Medical Officer
  • Stephane Hauduc
    Chemistry & Intellectual Property Manager
  • Ian Hayter
    Project Director of Pharmaceutical Development
  • William Rhys-Williams
    Project Director of Microbiology & Pre-clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.